Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Inoperable Locally Advanced Breast Cancer|Metastatic Breast Cancer (MBC)
Interventions: DRUG: BEZ235|DRUG: Paclitaxel
Sponsor: Novartis Pharmaceuticals